– Approximately $44 million and $125 million in preliminary (unaudited) Revuforj® (revumenib) 4Q25 and full year 2025 net revenue, respectively –  – Continued acceleration in demand following approval in R/R NPM1m AML, with an approximate 38% increase in Revuforj net revenue in 4Q25 vs. 3Q25 -  – $56 million and $152 million in preliminary (unaudited) Niktimvo™ (axatilimab-csfr) 4Q25 and full year 2025 net revenue, respectively; Syndax will report its share of the Niktimvo net profit when it reports full y ...

– Top-Line Data from the Phase 3 SENTRY Trial in Myelofibrosis on Track for March 2026 – – Top-Line Data from the Phase 3 XPORT-EC-042 Trial in Endometrial Cancer on Track for Mid-2026 – ®– Preliminary Unaudited Full Year 2025 Total Revenue and U.S. XPOVIO (selinexor) Net Product Revenue Expected to be Approximately $145 Million and $115 Million, Respectively – NEWTON, Mass., Jan. 12, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel ...

Core Viewpoint - Arcus Biosciences, Inc. is facing challenges following the discontinuation of its Phase 3 STAR-221 study, which has negatively impacted investor sentiment and stock performance, despite a previously strong market position. Group 1: Stock Performance - Truist Financial has set a price target of $30 for Arcus Biosciences (RCUS), indicating a potential upside of 34.74% from its current trading price of $22.27 [1][5] - Following the announcement of the study's discontinuation, RCUS stock experienced a significant decline, dropping to $21.77, a decrease of 13.42% or $3.38 from its previous value [2][3] - The stock fluctuated between $20.35 and $24 during the trading day, reflecting market volatility [3] Group 2: Study Discontinuation - Arcus announced the discontinuation of its Phase 3 STAR-221 study in collaboration with Gilead Sciences, as the Independent Data Monitoring Committee found no improvement in overall survival with the tested combination [2][5] - The decision to halt the study has adversely affected investor sentiment, despite the safety profiles being similar [2] Group 3: Future Focus - Arcus is shifting its focus to research and development investments in Casdatifan and its emerging inflammation and immunology portfolio [4][5] - The company's market capitalization is approximately $2.35 billion, with a trading volume of 5,619,062 shares on the day of the announcement [4]

Core Insights - Crescent Biopharma is focused on advancing innovative therapies for cancer patients, with a vision to become a leading oncology company [2] Company Overview - Crescent Biopharma's pipeline includes a PD-1 x VEGF bispecific antibody and novel antibody-drug conjugates (ADCs) aimed at treating various solid tumors [2] - The company utilizes multiple modalities and established targets to develop transformative therapies, either as standalone treatments or in combination regimens [2] Upcoming Events - Crescent Biopharma will present at several investor conferences in November 2025, including: - Guggenheim 2 Annual Healthcare Innovation Conference on November 11, 2025, at 8:00 a.m. ET in Boston [3] - Stifel 2025 Healthcare Conference on November 12, 2025, at 1:20 p.m. ET in New York [3] - Jefferies Global Healthcare Conference on November 19, 2025, at 9:30 a.m. GMT (4:30 a.m. ET) in London [3]

Core Insights - Syndax Pharmaceuticals announced the acceptance of 23 abstracts, including six oral presentations, for the 67th American Society of Hematology (ASH) Annual Meeting, highlighting the company's advancements in menin inhibition and CSF-1R inhibition [1][2] Revumenib - Revumenib abstracts demonstrate promising results across various acute leukemia subtypes, including relapsed/refractory (R/R) settings and post-HSCT scenarios [1][2] - New frontline datasets will showcase the tolerability of Revumenib in combination with standard therapies, achieving high rates of complete remission and minimal residual disease (MRD) negativity [2][5] - The first real-world evidence for a menin inhibitor will be presented, along with a retrospective review of its use in post-transplant settings [2][5] - Key presentations include a Phase 2 study of Revumenib combined with venetoclax and decitabine/cedazuridine in newly diagnosed acute myeloid leukemia (AML) [7] - Additional presentations will cover efficacy and safety by leukemia type in patients with R/R KMT2Ar acute leukemia [7] Axatilimab - Axatilimab abstracts will focus on its long-term benefits in R/R chronic graft-versus-host disease (GVHD) and its tolerability when combined with ruxolitinib in newly diagnosed chronic GVHD [1][2] - An oral presentation will detail the safety and feasibility of transitioning dosing from 0.3 mg/kg every 2 weeks to 0.6 mg/kg every 4 weeks in the pivotal Phase 2 AGAVE-201 trial [4][10] - Presentations will also include interim safety analyses from a Phase 2 trial of axatilimab combined with ruxolitinib in newly diagnosed chronic GVHD [8][10] Company Overview - Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company focused on innovative cancer therapies, with a pipeline that includes Revuforj (revumenib) and Niktimvo (axatilimab) [44] - The company is committed to advancing its clinical trials across various treatment landscapes, aiming to unlock the full potential of its product candidates [44]

Core Insights - Syndax Pharmaceuticals will report its third quarter 2025 financial results and provide a business update on November 3, 2025 [1] - A conference call and live audio webcast will be hosted by Syndax's management at 4:30 p.m. ET on the same day [1] Company Overview - Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company focused on innovative cancer therapies [3] - The company's pipeline includes Revuforj (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody targeting the CSF-1 receptor [3] - Syndax is committed to advancing cancer care and is conducting several clinical trials across various treatment stages [3]

Core Insights - Adlai Nortye Ltd. is a clinical-stage biotechnology company focused on developing innovative cancer therapies and will present at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston from October 22-26, 2025 [1][2] Company Overview - Adlai Nortye operates globally with R&D centers in the U.S. and China, advancing a portfolio of innovative drug candidates in two key therapeutic areas: next-generation PD-1/L1 modulation and RAS-targeted therapies [3] - Key drug candidates include AN8025, a multifunctional fusion protein for T cell and antigen-presenting cell modulation; AN4005, a first-in-class oral small-molecule PD-L1 inhibitor; AN9025, an oral pan-RAS(ON) inhibitor; and AN4035, a novel CEACAM5-targeting antibody-drug conjugate [3]

Core Insights - Starpharma has signed a collaboration and license agreement with Genentech to develop cancer therapies using its proprietary DEP drug delivery technology [1] - The agreement includes an upfront payment of USD $5.5 million and potential milestones totaling up to USD $564 million, along with tiered royalties on global net sales [2][3] Company Overview - Starpharma is an innovative Australian biotechnology company focused on developing dendrimer-drug conjugates that incorporate Genentech medicines for oncology targets [3] - The DEP platform technology offers benefits such as improved solubility, increased efficacy, pharmacokinetic control, and better toxicity profiles, applicable to various drug classes [4] Strategic Goals - A key strategic priority for Starpharma is to establish high-impact partnerships to maximize the potential of its DEP platform, aiming to expand market reach and improve patient therapies [7] - The collaboration with Genentech is seen as a recognition of Starpharma's technology and a continuation of three years of collaborative research focused on cancer therapies [5][6]

Core Insights - Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer treatments that target specific vulnerabilities in cancer cells while minimizing damage to healthy cells [1][2] Presentation Details - Aprea will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025, at 3:30 PM ET, located at the Lotte New York Palace Hotel [2] - A webcast of the presentation will be available for 90 days on the Aprea Investors page [2] Company Overview - Aprea's mission is to create novel cancer therapies that directly target cancer cells, reducing toxicity risks associated with conventional treatments [2] - The company's lead programs include APR-1051, an oral small-molecule inhibitor of WEE1 kinase, and ATRN-119, a macrocyclic small molecule ATR inhibitor, both in clinical development for solid tumor indications [2]

Company Overview - SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) is a clinical-stage biopharmaceutical company focused on developing cancer therapies, particularly for hematologic malignancies [1] - The company's pipeline includes two candidates: Galinpepimut-S (GPS) and SLS009 (tambiciclib) [1] Product Pipeline - Galinpepimut-S (GPS) is an immunotherapy currently in Phase 3 clinical trials for acute myeloid leukemia (AML) [1] - SLS009 (tambiciclib) is another candidate in the company's pipeline, although specific details about its development stage are not provided [1]